Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration

Wallis, Steven C., Mullany, Dan V., Lipman, Jeffrey, Rickard, Claire M. and Daley, Peter J. (2001) Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. Intensive Care Medicine, 27 4: 665-672. doi:10.1007/s001340100857


Author Wallis, Steven C.
Mullany, Dan V.
Lipman, Jeffrey
Rickard, Claire M.
Daley, Peter J.
Title Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration
Journal name Intensive Care Medicine   Check publisher's open access policy
ISSN 0342-4642
1432-1238
Publication date 2001-04
Sub-type Article (original research)
DOI 10.1007/s001340100857
Volume 27
Issue 4
Start page 665
End page 672
Total pages 8
Editor K. J. Falke
Place of publication Germany
Publisher Springer-Verlag
Collection year 2001
Language eng
Subject C1
320500 Pharmacology and Pharmaceutical Sciences
730100 Clinical (Organs, Diseases and Abnormal Conditions)
110310 Intensive Care
Abstract Objectives: To investigate the pharmacokinetics of intravenous ciprofloxacin 200 mg every 8 h in critically ill patients on continuous veno-venous haemodiafiltration (CVVHDF), one form of continuous renal replacement therapy (CRRT). Design and setting: Open, prospective clinical study in a multidisciplinary, intensive care unit in a university-affiliated tertiary referral hospital. Patients: Sis critically ill patients with acute renal failure on CVVHDF. Interventions: Timed blood and ultrafiltrate samples were collected to allow pharmacokinetics and clearances to be calculated of initial and subsequent doses of 200 mg intravenous ciprofloxacin. CVVHD was performed with 1 l/h of dialysate and 2 l/h of predilution filtration solution, producing 3 lih of dialysis effluent. The blood was pumped at 200 ml/min using a Gambro BMM-10 blood pump through a Hospal AN69HF haemofilter,. Measurements and results: Ten pharmacokinetic profiles were measured. The CVVHDF displayed a urea clearance of 42 +/- 3 ml/min, and removed ciprofloxacin with a clearance of 37 +/- 7 ml/min. This rate was 2-2.5 greater than previously published for ciprofloxacin in other forms of CRRT. On average the CVVHDF was responsible for clearing a fifth of all ciprofloxacin eliminated (21 +/- 10%). The total body clearance of ciprofloxacin was 12.2 +/- 4.3 l/h. The trough concentration following the initial dose was 0.7 +/- 0.3 mg/l. The area under the plasma concentration time curves over a 24-h period ranged from 21 to 55 mg .h l(-1). Conclusions: Intravenous ciprofloxacin 600 mg/day in critically ill patients using this form of CRRT produced adequate plasma levels for many resistant microbes found in intensive care units.
Keyword Critical Care Medicine
Antibiotics
Ciprofloxacin
Pharmacokinetics
Continuous Renal Replacement Therapy
Sepsis
Renal Replacement Therapy
Critically Ill Patients
Intravenous Ciprofloxacin
Severe Sepsis
Hemofiltration
Hemodiafiltration
Pharmacodynamics
Hemodialysis
Disease
Serum
Q-Index Code C1

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 19 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 31 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 14 Aug 2007, 15:58:14 EST